相似文献
1
Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.
Vaccine. 2015 Feb 18;33(8):973-6. doi: 10.1016/j.vaccine.2015.01.007. Epub 2015 Jan 14.
2
Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
Hepatology. 2013 Apr;57(4):1303-13. doi: 10.1002/hep.26132. Epub 2013 Mar 14.
3
Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Antivir Ther. 2007;12(4):477-87.
4
Incorporation of apolipoprotein E into HBV-HCV subviral envelope particles to improve the hepatitis vaccine strategy.
Sci Rep. 2021 Nov 8;11(1):21856. doi: 10.1038/s41598-021-01428-7.
5
Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.
Vaccine. 2018 Apr 19;36(17):2273-2281. doi: 10.1016/j.vaccine.2018.03.036. Epub 2018 Mar 22.
6
DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV.
World J Gastroenterol. 2002 Jun;8(3):505-10. doi: 10.3748/wjg.v8.i3.505.
7
Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.
Mol Immunol. 2006 Feb;43(5):436-42. doi: 10.1016/j.molimm.2005.03.002. Epub 2005 Apr 2.
8
Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus.
Microb Cell Fact. 2016 Apr 13;15:62. doi: 10.1186/s12934-016-0460-4.
9
Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
J Virol. 2015 Oct;89(20):10407-15. doi: 10.1128/JVI.01184-15. Epub 2015 Aug 5.
10
Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies.
N Biotechnol. 2009 Apr;25(4):226-34. doi: 10.1016/j.nbt.2009.01.001. Epub 2009 Jan 21.
引用本文的文献
1
Current Hepatitis C Vaccine Candidates Based on the Induction of Neutralizing Antibodies.
Viruses. 2023 May 11;15(5):1151. doi: 10.3390/v15051151.
2
Immunogenicity of Wild Type and Mutant Hepatitis B Surface Antigen Virus-like Particles (VLPs) in Mice with Pre-Existing Immunity against the Wild Type Vector.
Viruses. 2023 Jan 23;15(2):313. doi: 10.3390/v15020313.
3
Incorporation of apolipoprotein E into HBV-HCV subviral envelope particles to improve the hepatitis vaccine strategy.
Sci Rep. 2021 Nov 8;11(1):21856. doi: 10.1038/s41598-021-01428-7.
4
To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity.
Viruses. 2021 Apr 30;13(5):805. doi: 10.3390/v13050805.
5
Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.
Viruses. 2020 Jan 21;12(2):126. doi: 10.3390/v12020126.
6
SnoopLigase peptide-peptide conjugation enables modular vaccine assembly.
Sci Rep. 2019 Mar 15;9(1):4625. doi: 10.1038/s41598-019-40985-w.
7
Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C.
Front Microbiol. 2017 Dec 5;8:2413. doi: 10.3389/fmicb.2017.02413. eCollection 2017.
8
The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine.
Front Microbiol. 2017 Nov 7;8:2163. doi: 10.3389/fmicb.2017.02163. eCollection 2017.
9
Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8 T-cell response.
Sci Rep. 2017 Aug 29;7(1):9630. doi: 10.1038/s41598-017-08787-0.
10
Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus.
Microb Cell Fact. 2016 Apr 13;15:62. doi: 10.1186/s12934-016-0460-4.
本文引用的文献
1
Response to booster doses of hepatitis B vaccine among young adults who had received neonatal vaccination.
PLoS One. 2014 Sep 8;9(9):e107163. doi: 10.1371/journal.pone.0107163. eCollection 2014.
2
Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.
Clin Infect Dis. 2014 Nov 15;59(10):1411-9. doi: 10.1093/cid/ciu643. Epub 2014 Aug 11.
3
Hepatitis B virus infection.
Lancet. 2014 Dec 6;384(9959):2053-63. doi: 10.1016/S0140-6736(14)60220-8. Epub 2014 Jun 18.
4
Bioengineering virus-like particles as vaccines.
Biotechnol Bioeng. 2014 Mar;111(3):425-40. doi: 10.1002/bit.25159. Epub 2013 Dec 17.
5
Treatment as prevention and cure towards global eradication of hepatitis C virus.
Trends Microbiol. 2013 Dec;21(12):625-33. doi: 10.1016/j.tim.2013.09.008. Epub 2013 Nov 14.
6
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.
Nat Med. 2013 Jul;19(7):837-49. doi: 10.1038/nm.3248.
7
The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease.
Top Antivir Med. 2013 Feb-Mar;21(1):15-9.
8
Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine.
Biotechnol Bioeng. 2013 Sep;110(9):2343-51. doi: 10.1002/bit.24907. Epub 2013 Apr 22.
9
Prospects for prophylactic hepatitis C vaccines based on virus-like particles.
Hum Vaccin Immunother. 2013 May;9(5):1112-8. doi: 10.4161/hv.23900. Epub 2013 Feb 13.
10
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.
Hepatology. 2013 Apr;57(4):1333-42. doi: 10.1002/hep.26141. Epub 2013 Feb 4.
Zotero 插件